SYNERGEN CONSIDERING "STRATEGIC ALTERNATIVES" AFTER ANTRIL SEPSIS FAILURE
Executive Summary
SYNERGEN CONSIDERING "STRATEGIC ALTERNATIVES" AFTER ANTRIL SEPSIS FAILURE, including the sale or merger of the company, Synergen CEO Gregory Abbott said in a July 18 teleconference announcing the interim results of the Antril Phase III follow-up study. The company halted the trial for lack of efficacy of the interleukin-1 receptor antagonist in sepsis patients with organ dysfunction and/or shock.